Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26605352
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26605352
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Eye+Vis+(Lond)
2014 ; 1
(ä): 5
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Presbyopic correction on the cornea
#MMPMID26605352
Arba Mosquera S
; Alió JL
Eye Vis (Lond)
2014[]; 1
(ä): 5
PMID26605352
show ga
PURPOSE: The aim of this systematic review was to synthesize and appraise the
evidence of the benefits of presbyopic correction on the cornea for visual
function. SUMMARY: Comprehensive search was conducted in MEDLINE using keywords
like "presbylasik", "presbyopic refractive surgery", "corneal
pseudoaccommodation" and "corneal multifocality". We reviewed corrected and
uncorrected visual acuities for distance and near (uncorrected distance visual
acuity (UDVA), uncorrected near visual acuity (UNVA), corrected distance visual
acuity (CDVA), distance corrected near visual acuity (DCNVA), corrected near
visual acuity (CNVA)), along with the refractive outcomes in spherical equivalent
(SE) and astigmatism comparing the differences observed between preoperative
myopic and hyperopic patients, as well as among techniques. Thirty-one studies
met the inclusion and quality criteria. Monovision provides excellent distance
and near uncorrected acuities, but with a 17% retreatment and a 5% reversal rate.
Initial multifocal ablations result in 12% loss of 2 or more lines of CDVA, and a
21% retreatment rate. Laser Blended Vision provides excellent UDVA, but with a
19% retreatment rate. Initial experiences with Supracor show moderate
predictability and a 22% retreatment rate. Intracor results in 9% loss of 2 or
more lines of CDVA. KAMRA provides excellent UDVA, with only a 1% retreatment
rate, but a 6% reversal rate. Initial experiences with PresbyMAX provided
excellent UNVA and DCNVA, showing excellent predictability and a 1% reversal
rate. CONCLUSIONS: The findings have implications for clinicians and policymakers
in the health-care industry and emphasize the need for additional trials
examining this important and widely performed clinical procedure.